PD-L1 on MC38 tumor cells can directly inhibit CD8+ T cell responses and reduce CD8+ T cell cytotoxicity and the CD8+ ratio relative to Treg cells (Juneja et al., 2017). The gene discussed is CD8A; the disease is neoplasm.